You just read:

Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine

News provided by

Braeburn Pharmaceuticals

May 14, 2018, 11:12 ET